Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05368818 · ClinicalTrials.gov registry record
An Analysis of the Improvement and Quality of Life Trends for UK/ROI Patients Treated With Cosentyx (Secukinumab) in a Retrospective Analysis of the BADBIR Data Source
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 767
- Enrollment target
NCT05368818 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 767 participants.
The verdict
NCT05368818 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 767 participants
- Enrollment target
Study Summary
This was a retrospective, observational study of psoriasis patients treated with secukinumab, using secondary data from BADBIR. BADBIR is a UK/ROI pharmacovigilance registry that was initiated in 2007 to monitor the long-term safety of biologic drugs used to treat psoriasis. The study used longitudinal data within the registry to track the trends relating to the disease. For the analysis of improvement and patient reported QoL, patients with a minimum of one follow-up visit were included. The index date was defined as the date of initiation of secukinumab treatment, and follow-up visits were at 6-, 12-, 18-, \& 24-months post-index.
Interventions
- OTHER Secukinumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 767 participants |
| Start Date | 2020-12-07 |
| Est. Completion | 2021-05-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05368818
The ClinicalTrials.gov registry entry for NCT05368818 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 767 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Secukinumab is the first listed.
NCT05368818 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05368818 about?
NCT05368818 is a clinical study titled "An Analysis of the Improvement and Quality of Life Trends for UK/ROI Patients Treated With Cosentyx (Secukinumab) in a Retrospective Analysis of the BADBIR Data Source". This was a retrospective, observational study of psoriasis patients treated with secukinumab, using secondary data from BADBIR. BADBIR is a UK/ROI pharmacovigilance registry that was initiated in 2007 to monitor the long-term safety of biologic drugs used to treat psoriasis. The study used longitudi...
What is the current status of trial NCT05368818?
This trial is currently completed. The enrollment target is 767 participants. The study started on 2020-12-07. Estimated completion is 2021-05-06.
What interventions are being tested in trial NCT05368818?
The interventions under investigation include: Secukinumab (OTHER).
Who is sponsoring clinical trial NCT05368818?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.